1 unchanged sentence
(c) Trading Plans
−Removed: During the quarter ended December 31, 2023, no director or officer adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement.
+Added: During the quarter ended March 31, 2024, the following directors and officers (as defined in Exchange Act Rule 16a-1(f)) adopted certain trading plans intended to satisfy Rule 10b5-1(c):
+Added: Name Title Adoption Date Plan Start Date Plan End Date Shares
+Added: James Hamilton Chief Discovery and Translational Medicine 3/26/2024 1/6/2025 1/17/2025 60,000 n/a
+Added: Ken Myszkowski Chief Financial Officer 3/12/2024 6/11/2024 2/28/2025 n/a 115,000
+Added: Ken Myszkowski Chief Financial Officer 3/28/2024 1/6/2025 1/17/2025 15,000 n/a
+Added: Ken Myszkowski Chief Financial Officer 3/28/2024 1/6/2025 1/17/2025 15,000 n/a
+Added: Ken Myszkowski Chief Financial Officer 3/28/2024 1/6/2025 1/17/2025 15,000 n/a
+Added: Ken Myszkowski Chief Financial Officer 3/28/2024 1/6/2025 1/17/2025 18,750 n/a
+Added: Patrick O'Brien Chief Operating Officer and General Counsel 3/21/2024 1/6/2025 1/17/2025 67,500 n/a
+Added: William Waddill Board Member 3/27/2024 12/16/2024 12/31/2024 n/a 7,495
+Added: (1) This column indicates the total number of shares vesting in connection with equity awards, not the number of shares to be sold.
+Added: The actual number of shares to be sold will be a smaller number based on whatever is required to satisfy payment of applicable withholding taxes under sell-to-cover arrangements.
Number Document Description
3 unchanged sentences
3.3 Second Amended and Restated Bylaws of Arrowhead Pharmaceuticals, Inc., as amended January 24, 2023(incorporated by reference from Exhibit 3.3 of the Company’s Form 10-Q filed on May 2, 2023)
−Removed: Ame nded and Restated License Agreemen t, dated as of December 11 , 202 3 , by and between Arrowhead Pharmaceuticals, Inc.
−Removed: and GlaxoSmithKline Intellectual Property (No.
+Added: Arrowhead Pharmaceuticals, Inc.
+Added: Inducement Plan
31.1* Certification of Chief Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
16 unchanged sentences
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly authorized.
−Removed: February 6, 2024
ARROWHEAD PHARMACEUTICALS, INC.
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.